van Megen HJ - Search Results

1

On the significance of cholecystokinin receptors in panic disorder.

van Megen HJ, den Boer JA, Westenberg HG. van Megen HJ, et al. Prog Neuropsychopharmacol Biol Psychiatry. 1994 Dec;18(8):1235-46. doi: 10.1016/0278-5846(94)90090-6. Prog Neuropsychopharmacol Biol Psychiatry. 1994. PMID: 7863014 Review.

2

The panicogenic effects of cholecystokinin-tetrapeptide are antagonized by L-365,260, a central cholecystokinin receptor antagonist, in patients with panic disorder.

Bradwejn J, Koszycki D, Couëtoux du Tertre A, van Megen H, den Boer J, Westenberg H. Bradwejn J, et al. Arch Gen Psychiatry. 1994 Jun;51(6):486-93. doi: 10.1001/archpsyc.1994.03950060050005. Arch Gen Psychiatry. 1994. PMID: 8192551 Clinical Trial.

3

Pentagastrin induced panic attacks: enhanced sensitivity in panic disorder patients.

van Megen HJ, Westenberg HG, den Boer JA, Haigh JR, Traub M. van Megen HJ, et al. Psychopharmacology (Berl). 1994 Apr;114(3):449-55. doi: 10.1007/BF02249335. Psychopharmacology (Berl). 1994. PMID: 7855203 Clinical Trial.

4

The panic-inducing properties of the cholecystokinin tetrapeptide CCK4 in patients with panic disorder.

van Megen HJ, Westenberg HG, Den Boer JA, Kahn RS. van Megen HJ, et al. Eur Neuropsychopharmacol. 1996 Aug;6(3):187-94. doi: 10.1016/0924-977x(96)00018-1. Eur Neuropsychopharmacol. 1996. PMID: 8880078 Clinical Trial.

5

Effect of the cholecystokinin-B receptor antagonist L-365,260 on lactate-induced panic attacks in panic disorder patients.

van Megen HJ, Westenberg HG, den Boer JA. van Megen HJ, et al. Biol Psychiatry. 1996 Oct 15;40(8):804-6. doi: 10.1016/0006-3223(96)00250-8. Biol Psychiatry. 1996. PMID: 8894076 Clinical Trial. No abstract available.

6

Cholecystokinin in anxiety.

van Megen HJ, Westenberg HG, den Boer JA, Kahn RS. van Megen HJ, et al. Eur Neuropsychopharmacol. 1996 Nov;6(4):263-80. doi: 10.1016/s0924-977x(96)00038-7. Eur Neuropsychopharmacol. 1996. PMID: 8985709 Review.

7

The cholecystokinin-B receptor antagonist CI-988 failed to affect CCK-4 induced symptoms in panic disorder patients.

van Megen HJ, Westenberg HG, den Boer JA, Slaap B, van Es-Radhakishun F, Pande AC. van Megen HJ, et al. Among authors: van es radhakishun f. Psychopharmacology (Berl). 1997 Feb;129(3):243-8. doi: 10.1007/s002130050186. Psychopharmacology (Berl). 1997. PMID: 9084062 Clinical Trial.

8

Effect of the selective serotonin reuptake inhibitor fluvoxamine on CCK-4 induced panic attacks.

van Megen HJ, Westenberg HG, den Boer JA, Slaap B, Scheepmakers A. van Megen HJ, et al. Psychopharmacology (Berl). 1997 Feb;129(4):357-64. doi: 10.1007/s002130050201. Psychopharmacology (Berl). 1997. PMID: 9085405 Clinical Trial.

9

Sumatriptan (5-HT1D receptor agonist) does not exacerbate symptoms in obsessive compulsive disorder.

Pian KL, Westenberg HG, van Megen HJ, den Boer JA. Pian KL, et al. Among authors: van megen hj. Psychopharmacology (Berl). 1998 Dec;140(3):365-70. doi: 10.1007/s002130050777. Psychopharmacology (Berl). 1998. PMID: 9877016 Clinical Trial.

10

Effect of a pharmacological intervention on quality of life in patients with obsessive-compulsive disorder.

Tenney NH, Denys DA, van Megen HJ, Glas G, Westenberg HG. Tenney NH, et al. Among authors: van megen hj. Int Clin Psychopharmacol. 2003 Jan;18(1):29-33. doi: 10.1097/00004850-200301000-00005. Int Clin Psychopharmacol. 2003. PMID: 12490772 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

69 results

Search Page